Medications
How long has Ozempic been on the market? A short timeline
July 15, 2026 · 2 min read
The short answer
Ozempic (semaglutide) was approved by the FDA in December 2017 for type 2 diabetes, so it has been on the US market since 2018. Wegovy, the same drug at weight-management doses, followed in 2021.
The wider GLP-1 class is considerably older: the first GLP-1 receptor agonist was approved in 2005, and liraglutide (Victoza) in 2010. That two-decade class history is why the main risks are reasonably well characterized.
The short answer
Ozempic was approved by the US Food and Drug Administration in December 2017 and reached patients in 2018. So as of now it has roughly eight years of real-world use behind it in the United States, plus the years of clinical trials that preceded approval.
The timeline
| Year | Milestone |
|---|---|
| 2005 | Exenatide (Byetta), the first GLP-1 receptor agonist, approved |
| 2010 | Liraglutide (Victoza) approved for type 2 diabetes |
| 2014 | Liraglutide approved for weight management as Saxenda |
| 2017 | Ozempic (semaglutide) approved for type 2 diabetes |
| 2019 | Rybelsus, oral semaglutide, approved |
| 2021 | Wegovy (semaglutide 2.4 mg) approved for weight management |
| 2022 | Mounjaro (tirzepatide) approved for type 2 diabetes |
| 2023 | Zepbound (tirzepatide) approved for weight management; SELECT cardiovascular results published |
| 2024 | Zepbound approved for obstructive sleep apnea with obesity |
Why the class history matters more than the brand
People usually ask "how long has Ozempic been around" because they want to know whether the risks are understood. For that question, the class timeline is the more useful number. GLP-1 receptor agonists have been in clinical use since 2005, which means the characteristic effects (the gastrointestinal profile, the pancreatitis and gallbladder signals, the thyroid C-cell warning carried from rodent studies) have been watched across two decades and millions of patient-years.
Semaglutide specifically has also been through unusually large outcome trials since approval, including SELECT, which followed more than 17,000 people and reported cardiovascular benefit. That is a lot more scrutiny than most medications receive in their first decade.
What is genuinely still new
Two honest caveats. First, the very high doses used for weight management (semaglutide 2.4 mg, tirzepatide up to 15 mg) are newer than the diabetes doses, so the longest-term data at those doses is still accumulating. Second, the newest agents have shorter records: tirzepatide arrived in 2022, and the drugs generating headlines now (retatrutide, orforglipron, CagriSema) are not approved at all. Our emerging-drug guides cover those.
The practical read
Ozempic is not a brand-new experiment; it is an eight-year-old drug in a twenty-year-old class with large outcome trials behind it. It is also not a drug with fifty years of history like metformin. Both things are true, and where you land on that is a conversation with your prescriber rather than a number to settle it. Our safety post covers what the known risks actually are.
Questions people ask
How long has Ozempic been on the market?
Ozempic (semaglutide) was FDA-approved in December 2017 and reached patients in 2018, so it has around eight years of real-world use in the US, plus the trial years before approval.
How long have GLP-1 drugs been around?
Since 2005, when exenatide (Byetta) became the first approved GLP-1 receptor agonist. Liraglutide followed in 2010. That two-decade class history is why the characteristic risks are reasonably well characterized.
When was Wegovy approved?
Wegovy, which is semaglutide at weight-management doses up to 2.4 mg, was approved in 2021. It is the same active drug as Ozempic under a different label and dose.
Are GLP-1 drugs too new to be safe?
The class has been in use since 2005 and semaglutide has been through very large outcome trials, so the main risks are well described. The honest caveat is that the highest weight-management doses are newer, and the newest agents like tirzepatide have shorter records still.
References
- 1.FDA approval history for semaglutide (Ozempic, Rybelsus, Wegovy). Find on PubMed ↗
- 2.FDA approval history for exenatide, liraglutide, and tirzepatide. Find on PubMed ↗
- 3.Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. SELECT. NEJM 2023. Read on NEJM ↗
This article is general education, not medical advice. DoseLog is a tracking and reflection tool. Decisions about your medication, dose, and symptoms belong with a licensed clinician.
Keep reading